The Selection of DNA Aptamers for the Prevention of Alpha-Synuclein Aggregation as a Therapeutic Tool in Parkinson's Disease

It appears your Web browser is not configured to display PDF files. Download adobe Acrobat or click here to download the PDF file.

Click here to download the PDF file.

Creator: 

Callahan, Joshua

Date: 

2017

Abstract: 

Alpha-synuclein misfolding and aggregation are hallmarks for the progression of Parkinson’s disease. Aptamer based treatments could be well suited to the prevention of this aggregation. Aptamers are single stranded oligonucleotides which bind to a specific chemical target with high affinity and specificity. Aptamer sequences are discovered through a process known as SELEX (the systematic evolution of ligands by exponential enrichment). Here, starting pools of aptamer candidates are derived from a 2010 SELEX by Tsukakoshi et al. These pools, coupled with a novel SELEX method which employs the aggregation of alpha-synuclein, has yielded promising results towards the use of aptamers for the prevention of alpha-synuclein aggregation. Based on the combination of sequencing data, the probability of forming a G-quadruplex structure, and preliminary in vitro aggregation prevention assays, the aptamer ASYN2 has been selected as an introductory candidate for in vivo testing.

Subject: 

Neuroscience
Pharmacology
Analytical Chemistry

Language: 

English

Publisher: 

Carleton University

Thesis Degree Name: 

Master of Science: 
M.Sc.

Thesis Degree Level: 

Master's

Thesis Degree Discipline: 

Chemistry

Parent Collection: 

Theses and Dissertations

Items in CURVE are protected by copyright, with all rights reserved, unless otherwise indicated. They are made available with permission from the author(s).